CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. has a license, development, and commercialization agreement with United Therapeutics Corporation for 3D bioprinting of solid-organ scaffolds for human transplants. The company is headquartered in Ness Ziona, Israel.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-73-232-5600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$480,000.00
Profitability
Miscellaneous
Employees29
Next Earnings Date3/20/2019 (Estimated)
OptionableNot Optionable
COLLPLANT HOLDI/S (NASDAQ:CLGN) Frequently Asked Questions
What is COLLPLANT HOLDI/S's stock symbol?
COLLPLANT HOLDI/S trades on the NASDAQ under the ticker symbol "CLGN."
When is COLLPLANT HOLDI/S's next earnings date?
What price target have analysts set for CLGN?
1 brokers have issued twelve-month price objectives for COLLPLANT HOLDI/S's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate COLLPLANT HOLDI/S's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price. View Analyst Price Targets for COLLPLANT HOLDI/S.
What is the consensus analysts' recommendation for COLLPLANT HOLDI/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COLLPLANT HOLDI/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for COLLPLANT HOLDI/S.
Has COLLPLANT HOLDI/S been receiving favorable news coverage?
Press coverage about CLGN stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. COLLPLANT HOLDI/S earned a news impact score of 0.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of COLLPLANT HOLDI/S's key competitors?
What other stocks do shareholders of COLLPLANT HOLDI/S own?
Who are COLLPLANT HOLDI/S's key executives?
COLLPLANT HOLDI/S's management team includes the folowing people:
- Mr. Yehiel Tal, Chief Exec. Officer (Age 67)
- Prof. Oded Shoseyov, Founder & Chief Scientist Officer (Age 63)
- Mr. Eran Rotem, Deputy CEO & CFO (Age 51)
- Dr. Philippe David Bensimon, VP of Regulation Affairs & Quality Assurance (Age 54)
- Dr. Nadav Orr, VP of R&D (Age 62)
When did COLLPLANT HOLDI/S IPO?
(CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.
How do I buy shares of COLLPLANT HOLDI/S?
Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is COLLPLANT HOLDI/S's stock price today?
One share of CLGN stock can currently be purchased for approximately $6.00.
How big of a company is COLLPLANT HOLDI/S?
COLLPLANT HOLDI/S has a market capitalization of $20.52 million and generates $480,000.00 in revenue each year. The company earns $-6,020,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. COLLPLANT HOLDI/S employs 29 workers across the globe.
What is COLLPLANT HOLDI/S's official website?
How can I contact COLLPLANT HOLDI/S?
COLLPLANT HOLDI/S's mailing address is 3 SAPIR ST. WEIZMANN SCIENCE PARK P.O.B. 4132, NESS-ZIONA L3, 74140. The company can be reached via phone at 972-73-232-5600 or via email at [email protected]
MarketBeat Community Rating for COLLPLANT HOLDI/S (NASDAQ CLGN)
MarketBeat's community ratings are surveys of what our community members think about COLLPLANT HOLDI/S and other stocks. Vote "Outperform" if you believe CLGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
